Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth - Reuters
Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxNQUM2ak5mV1hSTDU0UzlDQVoxVERuOTNXT1p5OTJmbkdjaWFlVHBnLTVORDZkQmdBY0hFYlZCZzJsaV9lZTl5QXBFMUFLNDBkYmxoRi1CUXZncTVOZnE3NXFzb1dGdG93d2Q3MHpQelNsLV9jbzREblJEMmtOSTZBbTkwaGxzc3ItV0RPNGJHNk04Ti1kaEQ0UG04ekxRNk94SHBuUFprcl9kY2Y3dmxuTjh5RHBaQWdlR1Y4T0hTTjRZY1QwMnhjaXJzQTJNZjl1WlpPUFFmcVBCTkNBc253?oc=5" target="_blank">Eli Lilly raises annual revenue forecast as GLP-1 drugs fuel growth</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui - Reuters
Novo Nordisk to license experimental GLP-1 pill from China's Hengrui Reuters
September 29, 2026 at 04:47 AMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMSanofi to pay Regeneron $1 billion upfront in expanded immunology deal - Reuters
Sanofi to pay Regeneron $1 billion upfront in expanded immunology deal Reuters
October 1, 2026 at 05:17 AMTesla's car business back on growth path as deliveries beat forecasts - Reuters
Tesla's car business back on growth path as deliveries beat forecasts Reuters
October 2, 2026 at 02:49 PMSynopsys shares jump on robust growth outlook, OpenAI and AWS deals - Reuters
Synopsys shares jump on robust growth outlook, OpenAI and AWS deals Reuters
October 1, 2026 at 04:22 PM